Previous 10 | Next 10 |
Axonics, Inc. (AXNX) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants Raymond Cohen – Chief Executive Officer & Director Neil Bhalodkar – Vice President of Investor Relations Dan Dearen – President & Chief Financial Officer Confe...
Axonics Modulation Technologies press release (NASDAQ:AXNX): Q4 GAAP EPS of -$0.34 beats by $0.02. Revenue of $53.1M (+52.6% Y/Y) beats by $2.58M. For further details see: Axonics Modulation Technologies GAAP EPS of -$0.34 beats by $0.02, revenue of $53.1M beats by $2.58M
Total revenue of $53.1 million in 4Q21, an increase of 53% year over year Fiscal year 2022 revenue outlook of $234 million, an increase of 30% year over year Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing nove...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24,...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022. Axonics is s...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) preva...
Quarterly revenue exceeds $50 million for the first time Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net reven...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W. Cohen, chief executive officer of Axonics, has been awarded the 2021 Lifetime Entre...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 1 on the Deloitte Technology Fast 500™ , a ranking of the 500 fastest-grow...
Deloitte Unveils 2021 North America Technology Fast 500 Rankings California-based global medical technology company claims top spot in 27th annual ranking of fastest-growing businesses PR Newswire SAN FRANCISCO , Nov. 17, 2021 /PRNewswire/ -- Deloitte today r...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...